Quanterix Corporation successfully completed its strategic acquisition of Akoya Biosciences, Inc., establishing an integrated market leader capable of measuring protein biomarkers across both the blood and tissue continuum. The all-stock and cash transaction combined Quanterix's ultra-sensitive Simoa blood-based biomarker detection platform with Akoya's advanced spatial biology and single-cell tissue imaging technologies. This corporate integration expanded the combined enterprise's total addressable market significantly, creating a comprehensive portfolio designed to accelerate early disease diagnosis and pharmaceutical research in oncology, immunology, and neurology.